Insilc: A State-of-the-art digital clinical trial platform

The EU-funded InSilc project has developed a state-of-the-art digital clinical trial platform for assessing coronary artery treatment in a virtual environment.

Coronary artery disease remains the leading cause of mortality worldwide and accounts for over 4 million deaths per year – close to half of all deaths in Europe. Coronary stents are currently the most widely used devices for treating symptomatic coronary disease. The success of this treatment depends on optimal device designs and suitable implantation procedures by the surgeon.

Since 2017, the InSilc experts from Belgium, Greece, Italy, Ireland, the Netherlands, Serbia, the United Kingdom and the US have been working to develop the state-of-the-art InSilc Cloud based platform. This new technology integrates the latest in silico multiscale and multidisciplinary models and enables advanced prediction of the optimal performance of drug-eluting stents and bioresorbable vascular scaffolds in the treatment of coronary artery disease interventions.

Virtual Clinical Trials

The InSIlc cloud platform enables virtual clinical trials for coronary devices, enabling detailed predictions of the implantation procedure by simulating device deployment in patient-specific geometries. The InSilc cloud platform also provides predictions of medium- and long-term performance by predicting re-perfusion of the coronary arteries following device implantation, drug-delivery into the surrounding vessel, fluid flow and restenosis around the implanted stent and degradation of the device over time.

Better assessment and reduced complications

By integrating the information obtained from these different in-silico predictive models, InSilc enables the development, assessment and optimization of coronary stents and bioabsorbable vascular scaffolds, delivering accurate and reliable information to the Stent Biomedical Industry. The cloud platform also has the potential to assist interventional cardiologists in improving the surgical process of device implantation and supports them in the clinical assessment and reduces the complications of suboptimal scaffold performance.

InSilc Deployment Prediction

EU and transatlantic cooperation

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 777119 and integrates research groups, universities and companies from Belgium, Greece, Italy, Ireland, Netherlands, Serbia, the United Kingdom and the US. For further information please visit the project website http://www.insilc.eu

Final project press release on 30th April 2021